Article Information
History
- June 22, 2023.
Article Versions
- Version 1 (December 9, 2021 - 22:31).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Shek Man Chim1,
- Kristen Howell1,
- John Dronzek1,
- Weizhen Wu1,
- Cristopher Van Hout1,
- Manuel Allen Revez Ferreira1,
- Bin Ye1,
- Alexander Li1,
- Susannah Brydges2,
- Vinayagam Arunachalam1,
- Anthony Marcketta1,
- Adam E Locke1,
- Jonas Bovijn1,
- Niek Verweij1,
- Tanima De1,
- Luca Lotta1,
- Lyndon Mitnaul1,
- Michelle G. LeBlanc1,
- Regeneron Genetics Center1,
- DiscovEHR collaboration3,
- David Carey3,
- Olle Melander4,
- Alan Shuldiner1,
- Katia Karalis1,
- Aris N. Economides1,2,† and
- Harikiran Nistala1,†
- 1Regeneron Genetics Center, 777 Old Saw Mill River Road, Tarrytown NY
- 2Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown NY
- 3Geisinger Health System, Danville, PA
- 4Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden
- ↵†Corresponding Authors: Harikiran Nistala, Ph.D Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road, Tarrytown NY 10591 Phone: (732) 543 6367; Email: kiran.nistala{at}gmail.com Aris N. Economides, Ph.D. Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road, Tarrytown NY 10591 Email: aris.economides{at}regeneron.com
Posted June 22, 2023.
Genetic inactivation of zinc transporter SLC39A5 improves liver function and hyperglycemia in obesogenic settings
